LumiraDx Limited – NASDAQ:LMDX
LumiraDx Limited stock price monthly change
LumiraDx Limited stock price quarterly change
LumiraDx Limited stock price yearly change
LumiraDx Limited key metrics
Market Cap | N/A |
Enterprise value | 420.68M |
P/E | -0.27 |
EV/Sales | 1.26 |
EV/EBITDA | -1.90 |
Price/Sales | 0.51 |
Price/Book | 9.42 |
PEG ratio | N/A |
EPS | -1.1 |
Revenue | 126.51M |
EBITDA | -161.57M |
Income | -339.48M |
Revenue Q/Q | -53.03% |
Revenue Y/Y | -68.24% |
Profit margin | -101.51% |
Oper. margin | -57.88% |
Gross margin | 35.59% |
EBIT margin | -57.88% |
EBITDA margin | -127.71% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeLumiraDx Limited stock price history
LumiraDx Limited stock forecast
LumiraDx Limited financial statements
| Sep 2022 | 42.21M | -143.43M | -339.74% |
|---|---|---|---|
| Dec 2022 | 41.12M | -102.19M | -248.53% |
| Mar 2023 | 22.17M | -44.12M | -198.99% |
| Jun 2023 | 21.00M | -49.73M | -236.8% |
| 2025 | 194.11M | -79.02M | -40.71% |
|---|
Analysts Price target
Financials & Ratios estimates
| 2023-11-08 | -0.11 | -0.47 |
|---|
| Sep 2022 | 568709000 | 550.89M | 96.87% |
|---|---|---|---|
| Dec 2022 | 441013000 | 553.11M | 125.42% |
| Mar 2023 | 392308000 | 545.91M | 139.15% |
| Jun 2023 | 340827000 | 555.55M | 163% |
| Sep 2022 | -50.11M | -5.87M | 90.41M |
|---|---|---|---|
| Dec 2022 | -29.68M | -2.37M | -7.24M |
| Mar 2023 | -25.01M | -1.73M | -8.11M |
| Jun 2023 | -27.05M | -821K | -14.78M |
LumiraDx Limited alternative data
| Aug 2023 | 1,210 |
|---|---|
| Sep 2023 | 1,210 |
| Oct 2023 | 1,210 |
| Nov 2023 | 1,210 |
| Dec 2023 | 1,210 |
| Jan 2024 | 1,210 |
| Feb 2024 | 1,210 |
| Mar 2024 | 1,210 |
| Apr 2024 | 1,210 |
| May 2024 | 1,210 |
| Jun 2024 | 1,210 |
| Jul 2024 | 1,210 |
LumiraDx Limited other data
| Quarter | Transcript |
|---|---|
| Q2 2023 24 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Q1 2023 16 May 2023 | Q1 2023 Earnings Call Transcript |
| Q4 2022 21 Mar 2023 | Q4 2022 Earnings Call Transcript |
| Q3 2022 12 Nov 2022 | Q3 2022 Earnings Call Transcript |
-
When is LumiraDx Limited's next earnings date?
Unfortunately, LumiraDx Limited's (LMDX) next earnings date is currently unknown.
-
Does LumiraDx Limited pay dividends?
No, LumiraDx Limited does not pay dividends.
-
What is LumiraDx Limited's stock symbol?
LumiraDx Limited is traded on the NASDAQ under the ticker symbol "LMDX".
-
What is LumiraDx Limited's primary industry?
Company operates in the Healthcare sector and Medical - Diagnostics & Research industry.
-
How do i buy shares of LumiraDx Limited?
Shares of LumiraDx Limited can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does LumiraDx Limited have?
As Jul 2024, LumiraDx Limited employs 1,210 workers.
-
When LumiraDx Limited went public?
LumiraDx Limited is publicly traded company for more then 4 years since IPO on 19 Mar 2021.
-
What is LumiraDx Limited's official website?
The official website for LumiraDx Limited is lumiradx.com.
-
How can i contact LumiraDx Limited?
LumiraDx Limited can be reached via phone at +44 117 284 2535.
LumiraDx Limited company profile:
LumiraDx Limited
lumiradx.comNASDAQ
1,210
Medical - Diagnostics & Research
Healthcare
LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has approximately 30 tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions from the lab to point of need. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company was founded in 2014 and is headquartered in London, the United Kingdom.
London, SE1 2AQ
CIK: 0001685428
ISIN: KYG5709L1095
CUSIP: G5709L109
